Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Stavudine

FDA-approved product (capsule, oral), marketed as Stavudine, Zerit, Zerit Xr.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Stavudine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF04

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Stavudine, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA13.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli14.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis22.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Stavudine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Stavudine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment

    NCT00005017

    Registered record
    Registry ID
    NCT00005017
    Conditions
    HIV Infections
    Interventions
    Ritonavir; Abacavir sulfate; Amprenavir; Efavirenz; Lamivudine; Stavudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRitonavir; Abacavir sulfate; Amprenavir; Efavirenz +2 more
    PhasePhase 4
    Registry statusUnknown

  • A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection

    NCT00006154

    Registered record
    Registry ID
    NCT00006154
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Ritonavir; Abacavir sulfate; Efavirenz; Stavudine; Didanosine; Aldesleukin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Ritonavir; Abacavir sulfate; Efavirenz +3 more
    PhasePhase 3
    Registry statusCompleted

  • Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients

    NCT00007202

    Registered record
    Registry ID
    NCT00007202
    Conditions
    HIV Infections
    Interventions
    Atazanavir; Stavudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2006-10
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAtazanavir; Stavudine; Didanosine
    PhasePhase 2
    Registry statusCompleted

  • Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen

    NCT00014937

    Registered record
    Registry ID
    NCT00014937
    Conditions
    HIV Infections
    Interventions
    lopinavir/ritonavir; lamivudine/zidovudine; efavirenz; lamivudine; stavudine; zidovudine; didanosine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionlopinavir/ritonavir; lamivudine/zidovudine; efavirenz; lamivudine +3 more
    PhaseNot applicable
    Registry statusCompleted

  • A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation

    NCT00036452

    Registered record
    Registry ID
    NCT00036452
    Conditions
    HIV Infections
    Interventions
    lopinavir/ritonavir; emtricitabine; stavudine; tenofovir DF
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2006-01
    Enrolment
    402

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionlopinavir/ritonavir; emtricitabine; stavudine; tenofovir DF
    PhasePhase 2
    Registry statusCompleted